Join leading experts at the Third Annual Plasma Cell Disorders Symposium to explore the latest advances in #Immunotherapy, CAR T cell therapies, bispecific antibodies, and more. @mskcancercenter.bsky.social @mayocliniccancer.bsky.social Register here: https://cvent.me/7lkMy2

New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #AI-driven drug discovery initiative. Learn more: https://bit.ly/4uZZDHb

We're thrilled to welcome a new Associate Editor to Blood today! Dr. Omar Abdel-Wahab is the Evnin Family Chair of Molecular Pharmacology at @mskcancercenter.bsky.social where he also serves as Chair of the Molecular Pharmacology Program in the Sloan Kettering Institute. #NewEditor

The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. More about the clinical trials resulting in the drug’s approval, led by MSK's Dr. Sandra D’Angelo: https://bit.ly/4eVcTZ4

Novel #immunotherapy approaches such as T cell-engager therapies, CD40 agonists, and HSV-TK gene therapy have shown early promise for the treatment of #ProstateCancer. Read the review from Drs. Dallos, Gaffney, and @mskcancercenter.bsky.social collaborators. 📖 🔗 https://go.nature.com/4vRA5x7

New study alert: Roni Shouval & team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @mskcancercenter.bsky.social Read the study: https://bit.ly/4vYu0yL

A study led by @fungalspore.bsky.social found that higher levels of bacteria-derived valeric acid were associated with reduced Candida parapsilosis colonization in patients undergoing hematopoietic cell transplant, suggesting a potential strategy for preventing candidemia. https://bit.ly/3SI8ShD

Closing out strong, join MSK radiation oncologist Dr. Amy Xu at #ASCO26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations. 🕒 Tuesday, June 2 | 10:39 a.m. CDT Learn more: https://bit.ly/4x1m1ST

Coming up at #ASCO26: Join #melanoma medical oncologist Dr. Alexander Shoushtari for a presentation on how new tumor-infiltrating lymphocyte research can be translated into real benefit for patients. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 5:30 p.m. CDT Learn more: https://bit.ly/4nX5jjg

Join MSK's Dr. Michael Morris at #ASCO26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients w/ metastatic castration-resistant #prostatecancer previously treated with Lu-PSMA therapy. Learn more: meetings.asco.org/meetings/202...

“By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.” Learn more: www.mskcc.org/news/liver-c...

🚨 New findings presented at #ASCO26: An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC).

Join MSK medical oncologist Dr. Darren Feldman at #ASCO26 for an education session on optimizing treatment for patients with poor-risk testicular cancer, including a discussion on the management of brain metastasis. 🕒 Monday, June 1 | 1:51 p.m. CDT Learn more: https://bit.ly/4uEc3VN

Join MSK thoracic medical oncologist Dr. Jamie Chaft at #ASCO26 as she presents results from the phase III ALCHEMIST trial evaluating nivolumab after surgery and adjuvant chemotherapy in patients with non-small cell lung cancer. 🕒 Monday, June 1 | 1:15 p.m. CDT Learn more: https://bit.ly/3Q9i1Pw

Presenting our new study at #ASCO26 right now! Provider profits on cancer drugs have grown 4-fold to $40 billion in the last decade and a half. @ascocancer.bsky.social @mskcancercenter.bsky.social @hannahrabrams.bsky.social @nihcm.bsky.social

Join MSK radiation oncologist Dr. Luke Pike at #ASCO26 as he presents research on a machine learning-driven model designed to help predict brain metastasis risk in patients with breast cancer. 🕒 Monday, June 1 | 9:57 a.m. CDT Learn more: https://bit.ly/4fnVLfb

Presenting at #ASCO26 now! Our new study: Bribes from the drug industry can lead oncologists to use WORSE treatments (not just better ones) @ascocancer.bsky.social @mskcancercenter.bsky.social @dusetzinas.bsky.social @commonwealthfund.org @nihcm.bsky.social @arnoldventures.bsky.social

Join MSK sarcoma medical oncologist Dr. Mark Dickson at #ASCO26 as he participates as an expert in a case-based panel discussion on consensus and controversies in well-differentiated/dedifferentiated retroperitoneal liposarcoma. 🕒 Monday, June 1 | 11:30 a.m. CDT Learn more: https://bit.ly/4ojpetb

Join MSK thoracic medical oncologist Dr. Kathryn Arbour at #ASCO26 as she presents an overview of the latest advances in targeting #KRAS G12-mutant cancers. Not to be missed! @mskcancercenter.bsky.social @kcarbourmd.bsky.social 🕒 Monday, June 1 | 10:36 a.m. CDT Learn more: https://bit.ly/3RHEfZl

Join MSK gastrointestinal medical oncologist Dr. Ghassan Abou-Alfa at #ASCO26 as he presents efficacy and safety results from the phase 3 EMERALD-3 study. 🕒 Monday, June 1 | 9:45 a.m. CDT Learn more: https://bit.ly/4ecVY3A

Starting soon at #ASCO26: Dr. Ying Liu will present a poster on the NRG-GY036 trial comparing one vs. two years of maintenance olaparib (±bevacizumab) in #BRCA-mutated or HRD+ #OvarianCancer. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/49zWDcJ

WATCH: Alan L. Ho, MD, PhD, discusses the rationale for evaluating a ROR2-targeting antibody-drug conjugate in oropharyngeal squamous cell carcinoma. @mskcancercenter.bsky.social #hncsm #oncology See our head and neck cancers page for more insights! www.onclive.com/clinical/hea...

Join MSK hematology/oncology fellow Dr. Eric Jurgens at #ASCO26 for a poster on CAR T-cell detection and clonality in immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/4dEWXcK

Join MSK genitourinary medical oncologist Dr. Darren Feldman at #ASCO26 as he presents final results from a phase 2 trial of cabozantinib plus nivolumab for non-clear cell #RenalCellCarcinoma. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 9:12 a.m. CDT Learn more: https://bit.ly/4fiMdC6

Join MSK medical oncology fellow Dr. Ziad El Bakouny at #ASCO26 for a poster on the clinical and genomic factors that drive immune-related side effects across cancer types. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/4wY4ue6

Join MSK head and neck medical oncologist Dr. Alan Ho at #ASCO26 to learn about a phase 2 study of darolutamide plus leuprolide acetate for recurrent or metastatic AR-positive salivary gland cancer. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 8:48 a.m. CDT Learn more: https://bit.ly/3QdafEg

⚠️ New findings presented in the plenary session at #ASCO26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.

"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease." Learn more: www.mskcc.org/news/how-dar...

The phase 3 RASolute 302 study evaluated daraxonrasib, a RAS(ON) multi-selective inhibitor, versus chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma. 🕒 Sunday, May 31 | 3:21 p.m. CDT Learn more: meetings.asco.org/meetings/202...

Research co-authored by MSK gastrointestinal medical oncologist Dr. Eileen O’Reilly will be presented during the plenary session at #ASCO26.